Chemistry:Zabofloxacin
From HandWiki
| |
| Names | |
|---|---|
| Preferred IUPAC name
1-Cyclopropyl-6-fluoro-7-[(8E)-8-(methoxyimino)-2,6-diazaspiro[3.4]octan-6-yl]-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid | |
| Other names
DW-224a
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChemSpider | |
PubChem CID
|
|
| UNII | |
| |
| |
| Properties | |
| C19H20FN5O4 | |
| Molar mass | 401.392 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |
Tracking categories (test):
Zabofloxacin (DW-224a) is an investigational fluoroquinolone antibiotic for multidrug-resistant infections due to Gram-positive bacteria.[1][2][3][4] It also has activity against Neisseria gonorrhoeae including strains that are resistant to other quinolone antibiotics.[5]
Zabofloxacin was discovered by Dong Wha Pharmaceuticals and licensed to Pacific Beach BioSciences for development.[6]
A double-blind, three-arm clinical study of the drug began in March 2010.[7]
References
- ↑ HyeKyung Han; Sung Eun Kim; Kwang-Hee Shin; Cheolhee Lim; Kyoung Soo Lim; Kyung-Sang Yu; Joo-Youn Cho (October 2013). "Comparison of pharmacokinetics between new quinolone antibiotics: the zabofloxacin hydrochloride capsule and the zabofloxacin aspartate tablet". Current Medical Research and Opinion 29 (10): 1349–1355. doi:10.1185/03007995.2013.825591. PMID 23865727.
- ↑ Jong-Hwa Lee; Jung-Heun Ha; Dae-Hun Park; Dong-Rack Choi; Gye-Won Lee; Sung-Hoon Ahn; Choong-Yong Kim (2014). "Quantification Of Zabofloxacin In Rat Plasma Using Hplc-Uv Detector And Its Application To A Pharmacokinetic Study". Journal of Liquid Chromatography & Related Technologies 37 (3): 311–320. doi:10.1080/10826076.2012.745137.
- ↑ "Safety pharmacology of DW-224a, a novel fluoroquinolone antibiotic agent". Drug Chem Toxicol 27 (4): 295–307. Nov 2004. doi:10.1081/DCT-200039708. PMID 15573468.
- ↑ Park, Hee-Soo; Oh, Sang-Hun; Kim, Hye-Shin; Choi, Dong-Rack; Kwak, Jin-Hwan (2016-11-17). "Antimicrobial Activity of Zabofloxacin against Clinically Isolated Streptococcus pneumoniae". Molecules 21 (11): 1562. doi:10.3390/molecules21111562. ISSN 1420-3049. PMID 27869677.
- ↑ "Zabofloxacin (DW-224a) activity against Neisseria gonorrhoeae including quinolone-resistant strains". Diagn Microbiol Infect Dis 62 (1): 110–112. 2008. doi:10.1016/j.diagmicrobio.2008.05.010. PMID 18620833.
- ↑ "Pacific Beach BioSciences and Dong Wha Pharmaceuticals Sign Exclusive License Agreement to Develop and Commercialize Zabofloxacin (PB-101, DW-224a)". GlobeNewswire. August 10, 2007. http://globenewswire.com/news-release/2007/08/10/364043/124686/en/Pacific-Beach-BioSciences-and-Dong-Wha-Pharmaceuticals-Sign-Exclusive-License-Agreement-to-Develop-and-Commercialize-Zabofloxacin-PB-101-DW-224a.html.
- ↑ IASO Pharma Inc. (2012-05-04). A Phase 2, Multi-Dose, Double-Blind, Double-Dummy, Active-Control, Randomized Study to Evaluate the Safety, Efficacy and Pharmacokinetic Profile of Two Dosing Regimens of Zabofloxacin for the Treatment of Community-Acquired Pneumonia of Moderate Severity. https://clinicaltrials.gov/ct2/show/study/NCT01081964.
External links
 |  |
